LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Akcijų sąrašas・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

64.67 -3.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

63.67

Max

67.39

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-7.5M -190M
Pardavimai	33M 154M
Pelno marža	-123.403
Darbuotojai	834
EBITDA	-6.9M -180M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+58.35% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	361M 13B
Ankstesnė atidarymo kaina	67.7
Ankstesnė uždarymo kaina	64.67

Naujienos nuotaikos

By Acuity

50%

153 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

34.71 / 36.9 Palaikymas ir pasipriešinimas

Bridgebio Pharma Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-10 23:47; UTC

Rinkos pokalbiai

Gold Falls on Renewed Inflation Concerns -- Market Talk

2026-05-10 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026-05-10 23:38; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

2026-05-10 23:14; UTC

Rinkos pokalbiai

Australia's Political Map Continues to Be Redrawn -- Market Talk

2026-05-10 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium: Expects Deal to Close in 1Q FY27

2026-05-10 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

2026-05-10 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

2026-05-10 10:21; UTC

Uždarbis

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

2026-05-09 06:05; UTC

Uždarbis

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

2026-05-08 23:55; UTC

Uždarbis

Review & Preview: Still Going Strong -- Barrons.com

2026-05-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 20:49; UTC

Uždarbis

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026-05-08 20:25; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Net $115M

2026-05-08 19:20; UTC

Rinkos pokalbiai

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026-05-08 19:18; UTC

Uždarbis

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026-05-08 19:16; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:08; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:05; UTC

Uždarbis

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026-05-08 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026-05-08 18:51; UTC

Uždarbis

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026-05-08 18:49; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 18:41; UTC

Uždarbis

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026-05-08 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026-05-08 17:14; UTC

Uždarbis

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026-05-08 17:04; UTC

Rinkos pokalbiai

Zcash Caps Off Parabolic Week -- Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Bridgebio Pharma Inc Prognozė

Kainos tikslas

By TipRanks

58.35% į viršų

12 mėnesių prognozė

Vidutinis 106.71 USD 58.35%

Aukščiausias 157 USD

Žemiausias 81 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bridgebio Pharma Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

Pirkti

Laikyti

Parduoti

Remiantis 18 analitikų, pateikusių Bridgebio Pharma Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

34.71 / 36.9Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

153 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.